Talofen

Quick links to important sections

Talofen

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Talofen

What is Talofen, and What is its Active Ingredient?

Talofen is a trade name for a pharmaceutical product whose active ingredient is Promazine Hydrochloride, a synthetic organic compound belonging to the phenothiazine derivative chemical family. This medication is classified as a neuroleptic, a term used for antipsychotic agents. Promazine is one of the earlier compounds developed in its class and is utilized for achieving rapid tranquilization. The drug is a single-ingredient product, distinguishing it from combination medicines.


Talofen's Classification and Pharmaceutical Form

The medicine is classified as a typical antipsychotic (Phenothiazine antipsychotic), characterized by its core mechanism of dopamine antagonism. Promazine functions by blocking dopamine receptors in the brain, which is the basis for its physiological effects. Talofen is generally available in two primary dosage forms: solid oral tablets and a sterile aqueous solution intended for parenteral use (injection). This dual availability allows for different methods of administration: oral ingestion or rapid delivery during an acute crisis.


What is the General Purpose of Promazine?

The general purpose of Promazine is to achieve tranquilization and sedation for the management of severe states of psychomotor agitation and associated severely disturbed behavior. Its physiological effect is rooted in its broad activity on the central nervous system, including its antihistamine properties. This broad receptor activity results in central nervous system depression, providing a calming effect used to help stabilize patients during acute behavioral episodes. The drug also exerts an antiemetic (anti-nausea) effect, which may be useful when nausea is an accompanying issue.

Regulatory References

  1. Promazine Entry (NIH DrugBank)

What side effects are possible with Talofen?

Possible Side Effects and Safety Information

Talofen, which contains the phenothiazine derivative Promazine Hydrochloride, is associated with a safety profile derived from its mechanism of action, including effects on the central nervous system and cardiovascular system. All documented adverse reactions and safety restrictions are based on official governmental regulatory documents.

Serious and Clinically Significant Adverse Reactions

The most serious reported adverse reaction for this class of medication is Neuroleptic Malignant Syndrome (NMS), a potentially fatal complex characterized by high fever, muscle rigidity, altered mental status, and autonomic instability (e.g., irregular pulse, fluctuating blood pressure). Caution is also required due to the potential for fatal respiratory depression, especially in specific populations.

Promazine is also associated with extrapyramidal symptoms (involuntary movements such as tremors, rigidity, and dystonia), bone-marrow depression (leukopenia and agranulocytosis), and seizure threshold lowering.

System-Organ Class Common/Established Adverse Effects
Nervous System Sedation, Somnolence, Confusion, Dizziness, Dry Mouth, Blurred Vision
Cardiovascular Hypotension (low blood pressure), Tachycardia (fast heart rate)
Dermatologic Photosensitivity (increased sensitivity to sunlight), Dermatitis, Urticaria
Hematologic Leukopenia, Agranulocytosis

Population-Specific Safety Considerations and Restrictions

  • Pediatric Use: Official warnings strictly contraindicate the use of this medication in children under 2 years of age due to the risk of potentially fatal respiratory depression. Extreme caution is mandated for children 2 years of age and older, using the lowest effective dose.
  • Route of Administration: Regulatory warnings advise against subcutaneous (SC) and intra-arterial administration due to the risk of severe tissue injury, including necrosis and gangrene. Intramuscular (IM) administration is generally preferred over intravenous (IV) administration.
  • Existing Conditions: Use is restricted or requires caution in patients with severe cardiac disease, liver impairment, bone-marrow depression, or a history of seizures.

This safety information provides a high-level overview of the documented risks. Given the potential for serious adverse reactions like NMS and respiratory depression, its use is carefully managed under medical supervision.

Overdose and Emergency Response

The official regulatory documentation for Promazine Hydrochloride (Talofen) specifies that immediate medical attention must be sought if an overdose is suspected or confirmed. Patients are explicitly instructed to go to a hospital straight away if they have taken an amount exceeding the prescribed dose.

Overdose manifestations are documented to affect the Central Nervous System (CNS), presenting with drowsiness, confusion, convulsions, and coma. Cardiovascular effects include hypotension, sinus tachycardia, and pathological QT and QRS prolongation. Life-threatening outcomes such as Torsade de pointes and other severe ventricular arrhythmias are listed in official labeling, alongside rare risks like respiratory depression and renal failure.

The treatment described in regulatory documents is strictly symptomatic and supportive, as no specific antidote is known. Management procedures mandate maintaining a clear airway, correcting severe hypotension with agents like dopamine or dobutamine, and decontaminating the gastrointestinal tract using specific time constraints. Monitoring is required: Asymptomatic patients must be observed for at least four hours, and symptomatic patients require continuous cardiac rhythm monitoring with a 12-lead ECG. Special consideration is given to the elderly, who have increased susceptibility to hypotension and impaired temperature regulation, raising the risk of severe complications during overdose.

Therapeutic Uses of Talofen

What Talofen Treats: Main Uses and Benefits

Talofen (Promazine Hydrochloride) is commonly used for its supportive effects, generally applied in acute situations where symptoms may intensify temporarily. Its therapeutic scope addresses severe, acute symptomatic episodes when short-term symptomatic assistance is needed.

The medication is applied to address symptom clusters, including intense motor restlessness, heightened irritability, and uncontrollable behavior that creates noticeable physiological strain. The primary therapeutic support contributes to easing the overall symptom burden, which supports the patient during difficult episodes by easing distress and is relevant for easing challenging symptoms.

It may be used for acute behavioral disturbances that occur as part of underlying conditions such as schizophrenia, bipolar disorder, or agitation related to dementia and substance abuse. It assists with symptomatic support for severe, disruptive behavior, which helps ease the overall symptom load during episodes of heightened discomfort. It is also commonly used to help with the physical distress of nausea and vomiting.

“The medication is often used in clinical settings marked by temporary physiological imbalance, providing supportive relief when symptoms interfere with routine activities.”


Quick Fact: Relief for Acute Distress

  • Primary Context: Applied in clinical settings that involve acute or unstable symptom patterns.
  • Core Benefit: Provides support that helps ease the overall symptom burden.
  • Secondary Symptom Addressed: Nausea and vomiting.

Regulatory References

  1. NIH StatPearls overview of Phenothiazines

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Talofen — official regulatory information

Eligibility Scope

Category Regulatory Status (Official Labeling)
Populations for whom use is allowed Adults are permitted under standard labeled conditions. Older adults (geriatric population) are permitted, but caution is required.
Populations for whom use is not recommended Children (pediatric population). Older adults being treated for dementia-related behavioral disturbances (use is not licensed for this specific indication).
Populations for whom use is contraindicated Patients with known hypersensitivity to promazine or phenothiazines. Patients in a comatose state or with pre-existing CNS depression.
Pregnancy and lactation eligibility status Contraindicated during pregnancy and while lactating (breastfeeding).

Resulting Eligibility Structure

Official regulatory documents define Talofen's eligibility based on strict exclusions:

  • Contraindicated in individuals with bone marrow depression, phaeochromocytoma, or severe systemic conditions that compromise CNS function.
  • Use requires caution in patients with pre-existing conditions such as renal failure, liver dysfunction, cardiac disease, or epilepsy.
  • The medicine is not recommended for children and is not licensed for specific behavioral issues in older adults.

Connection to the overall eligibility profile: Official regulatory documents define Promazine Hydrochloride eligibility through a set of strict exclusions based on physiological state and concurrent medical conditions. The profile establishes absolute non-eligibility through formal contraindications, while establishing restricted use via specific warnings for patients with organ impairments or other chronic diseases.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for Talofen (Promazine Hydrochloride) outlines several mandated interaction restrictions based primarily on pharmacodynamic effects.


Formal Restrictions and Contraindications

Co-administration is formally contraindicated with large quantities of other Central Nervous System (CNS) Depressants, including alcohol, narcotics, and sedative/hypnotic agents. This restriction is due to the potential for additive sedative action which can be intensified or prolonged. Furthermore, the use of Epinephrine (adrenaline) is prohibited for treating hypotension that may be associated with Talofen administration, as Promazine has the potential to reverse the vasopressor effect of Epinephrine.


Administration-Timing and Dosage Rules

Certain co-administered CNS depressants require a mandatory dosage adjustment as specified in regulatory labeling. When combined with Talofen, the dose of Barbiturates must be reduced by at least one-half. Similarly, the dose of Narcotic Analgesics must be reduced by one-quarter to one-half to account for the heightened sedative effect. Additive pharmacodynamic effects may also occur with agents possessing anticholinergic properties or with Monoamine Oxidase Inhibitors (MAOIs), where an increased risk of extrapyramidal effects has been documented.


Population-Specific Notes

Caution is recommended when this product is administered in patients with hepatic impairment, as Promazine is metabolized in the liver. Concomitant use with Antihypertensives may also necessitate a dosage adjustment of the antihypertensive agent to manage the risk of orthostatic hypotension.

Mechanism of Action

Modulation of Central Neurotransmitter Systems

Talofen (Promazine Hydrochloride) exerts its effects by acting as an antagonist (blocker) at several G protein-coupled receptors within the central nervous system. The mechanism involves blocking Dopamine D2 receptors and Alpha-1 (alpha1) Adrenergic receptors. This antagonism reduces the amplitude of excitatory signaling within key circuits governing arousal and motor function, which are systems associated with activity modulation. The downstream consequence is a change in nerve impulse transmission in monoamine pathways.


Inducing Generalized CNS Depression

The drug's mechanism also involves the blockade of Histamine H1 receptors and Muscarinic Cholinergic receptors. By suppressing the activity of these pathways, which normally maintain wakefulness and autonomic tone, the drug initiates a generalized CNS depression and sedation as a consequence of reduced central nervous system activity.


Inhibition of the Emetic Reflex Cascade

The mechanism includes the specific action of blocking D2 receptors located in the Chemoreceptor Trigger Zone (CTZ) of the brainstem. This interference modifies the early molecular steps that normally activate the vomiting center, thus providing the physiological consequence of antiemesis.

Dosage and Administration Information

How Talofen (Promazine Hydrochloride) is Used: Official Administration Guidelines

Promazine Hydrochloride, the active ingredient in Talofen, is administered using strictly defined protocols that govern the route, frequency, and dosage adjustment patterns. The administration approach depends on whether the patient requires rapid stabilization during an acute episode or maintenance therapy.


Administration Scope

Property Official Instruction
Routes Oral (using tablets or syrup) and Intramuscular (IM) injection.
Acute Adult Dosing IM doses of 50 mg to 150 mg, repeatable after 30 minutes.
Maintenance Dosing Oral doses typically range from 10 mg to 200 mg per administration.
Frequency Doses are scheduled for administration every 4 to 8 hours or may be taken as a single dose at bedtime.
Max Daily Dose The total dosage must not exceed 1000 mg within a 24-hour period.

Use Protocol and Population Adjustments

The official protocol dictates that the medication is intended for short-term management only, requiring a necessary transition from the injectable form to the oral form once acute symptoms are controlled. The commencement or increase of dosage necessitates close clinical supervision, and the dose must be adjusted to the lowest effective amount.

For older adults, the regimen requires specific modification: these patients are typically started on a lower 25 mg dose and are restricted to a lower maximum daily intake of 200 mg. Standard protocols indicate that the treatment must be concluded using a gradual withdrawal process rather than abrupt cessation.

Recent Clinical Evidence

Research Evidence Overview and Study Landscape for Talofen (Promazine)


Evidence for use in Acute Psychomotor Agitation

Promazine has been used in research exploring how symptoms change over time in acute psychomotor agitation and severe behavioral disturbances. This is relevant in settings with varying symptom burdens, such as emergency psychiatric care, where symptoms like motor restlessness and heightened irritability become acute or disruptive.

Research includes short-term Randomized Controlled Trials (RCTs), systematic reviews, and meta-analyses. These studies monitored outcomes related to episodic or acute changes, primarily focusing on the time taken to observe patterns of sedation observed in the studies. Findings describe patterns observed in the measured time to reach a particular clinical state. However, comparative evidence is lacking in large, recent RCTs that directly compare Promazine monotherapy against current standard treatments for acute agitation. The evidence quality varies across studies, with many of the core data points derived from older research.


Evidence for use as an Antiemetic (Nausea and Vomiting)

The use of Promazine was evaluated in research exploring outcomes related to physical discomfort, specifically the symptomatic observation of nausea and vomiting. This application is often framed within the documented characteristics of the phenothiazine drug class.

Research in this area includes pharmacological reviews and historical data on clinical usage. Studies explored how the medication was observed in some studies for the short-term control of these symptoms. Data are still emerging from modern, dedicated trials comparing Promazine as a primary agent to newer, more targeted anti-nausea medications. Therefore, the current evidence is limited primarily to established properties and clinical observation patterns rather than recent comparative effectiveness studies.


Duration of Studies and Long-Term Follow-up

The vast majority of the research for Promazine was evaluated in scenarios exploring short-term symptom changes and immediate effects. The follow-up durations were limited, often focusing on the first hours after administration, consistent with the study designs for acute symptom observation. Consequently, long-term effects are not fully established. There is limited information for long-term outcomes that track sustained use and the long-term consistency of observed patterns. This means research provides context but not individual predictions regarding long-term response or the full profile of use.

Key Studies & References

  1. Phenothiazine - StatPearls - NCBI Bookshelf - NIH (General Antipsychotic/Antiemetic Class Monograph)
  2. Agitation and Aggression in the Elderly - U.S. Pharmacist (Review of typical antipsychotic use in older adults)

Frequently Asked Questions (FAQ)

Common questions about Talofen (FAQ)


Q: Does Talofen affect sleep patterns, and how?

A: Regulatory documents indicate that Promazine Hydrochloride, the active ingredient in Talofen, can cause central nervous system effects such as sedation, somnolence (drowsiness), and confusion. These effects may impact sleep patterns. While the medication is primarily known for its calming effect, official safety literature also reports paradoxical effects like insomnia.


Q: Can Talofen cause withdrawal symptoms if stopped suddenly?

A: Yes, official product information advises that acute withdrawal symptoms may occur if treatment with Talofen is stopped abruptly. Regulatory guidance advises that therapy should be concluded using a gradual withdrawal process, rather than abrupt cessation, to help manage the risk of acute withdrawal symptoms.


Q: Do other people experience vivid dreams or nightmares on Talofen?

A: Safety literature for this class of medication has included reports of vivid dreams or nightmares. This may be related to the drug's activity on the central nervous system, which can also lead to other effects like confusion.


Q: Does the time of day I take Talofen matter for its effectiveness?

A: Official administration instructions state that doses can be scheduled every 4 to 8 hours or taken as a single dose at bedtime. This indication allows for flexibility, where administration may be tailored by a healthcare professional to utilize the medication's sedative effects for specific needs.


Q: Does Talofen have a known risk for tardive dyskinesia?

A: Official warnings state that prolonged use of medications in this class may result in persistent movement disorders, including tardive dyskinesia, particularly in older adults. Official warnings note that if this condition develops, the healthcare provider typically initiates the withdrawal of the medication.


Q: Why is it important to keep taking Talofen even when feeling better?

A: Regulatory guidance dictates that when treatment needs to be concluded, it must be done through a gradual withdrawal process to avoid acute withdrawal symptoms. The medication should only be discontinued under the guidance of a healthcare professional to ensure a gradual withdrawal process, even when symptoms have improved.


Q: Does Talofen affect blood pressure or heart rate?

A: Yes, official safety information lists changes in cardiovascular function as established adverse effects. These include the potential for hypotension (low blood pressure) and tachycardia (fast heart rate). Caution is specifically required when prescribing Talofen to patients with pre-existing heart conditions.


Q: Can Talofen impact a person's ability to drive or operate machinery?

A: Yes, official product information cautions that Talofen may impair a person's ability to drive or operate complex machinery. This warning is based on potential side effects like sedation, somnolence, and blurred vision, which can affect reaction time and coordination.


Q: What are the signs of a serious, but rare, side effect from Talofen?

A: One of the most serious, though rare, reactions is Neuroleptic Malignant Syndrome (NMS). Regulatory documents describe the signs of NMS as high fever, severe muscle stiffness, significant changes in mental status, and autonomic instability, such as an irregular pulse or fluctuating blood pressure.


Q: How long does the therapeutic effect of a Talofen dose last?

A: Official administration guidelines recommend that doses are administered every 4 to 8 hours. This frequency suggests that the duration of the clinical effect is generally considered to be within this four-to-eight-hour timeframe.


Q: Is Talofen known to affect liver function?

A: Yes, caution is advised for patients with existing liver impairment. Official safety documents report that adverse effects can include abnormalities of liver function tests and, in rare instances, obstructive jaundice.


Q: Can Talofen be safely used by people with a history of seizures?

A: Official information states that caution is required for patients with a history of epilepsy or conditions predisposing them to seizures, as the medication may lower the seizure threshold.


Q: How often should someone check in with their doctor after starting Talofen?

A: Regulatory guidance specifies that when starting treatment or increasing the dosage, close clinical supervision is required. For prolonged or extended use, regular and careful monitoring is necessary to check for potential effects on the eyes, blood, liver, and heart function.


Q: Does Talofen cause changes in vision?

A: Yes, official safety information lists blurred vision as a possible adverse effect. Rarely, other visual changes, such as pain in the eye, loss of sight, or clouding of the lens, have also been reported.

How should Talofen be stored and disposed of?

How to Store and Dispose of Talofen?

Talofen (Promazine hydrochloride) must be stored and disposed of according to strict regulatory guidelines to maintain its stability and prevent accidental exposure.

Storage Requirements

Category Requirement
Temperature Store at controlled room temperature, typically 20°C to 25°C.
Protection Keep the medicine protected from excessive heat and moisture, in its original container.
Child Safety Store securely out of the sight and reach of children and household pets.
Stability Do not use the medicine after the expiration date printed on the packaging.

Disposal Instructions

Expired or unused Talofen should be disposed of by taking it to an authorized drug take-back location or through a mail-back program. If a take-back program is unavailable, do not flush the medicine. Instead, mix the product with an unappealing substance like used coffee grounds or dirt, seal the mixture in a bag, and discard it in the household trash. Before discarding, all personal information on the prescription label must be removed.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Talofen found in:

A-Z Index: